Regional anesthesia

A randomised controlled trial of intravenous dexmedetomidine added to dexamethasone for arthroscopic rotator cuff repair and duration of interscalene block

AnaesthesiaPublished Randomised controlled trial

Primary result · Time to first oral morphine intakeResult — go to the resultHazard ratio 1.68 95% CI 1.00–2.82

Authors' conclusion

In conclusion, dexmedetomidine shortened the time to oral morphine consumption after interscalene block combined with dexamethasone and caused intra-operative hypotension.

Study context

Population
Day-case arthroscopic rotator cuff repair with interscalene brachial plexus block after IV dexamethasone 0.15 mg.kg-1
Participants
122 participants
Comparison
Dexmedetomidine vs Placebo
  • Dexmedetomidinen = 60
  • Placebon = 62reference
Primary endpoint
Time from block to first oral morphine intake
Follow-up
First 48 postoperative hours

Primary result

Time to first oral morphine intake

Hazard ratio

1.68

95% CI 1.00–2.82

P = 0.049

Dexmedetomidine vs Placebo
HR 1.68 (95% CI 1.00–2.82); P = 0.049

As reported in the abstract

Further findings

Median, mg

OutcomeDexmedetomidinePlaceboDifference (mg) (95% CI)P value
Morphine dose10 (IQR [range] 0-30 [0-50])0 (IQR [range] 0-12.5 [0-50])7 (0–10)P = 0.056

Events

OutcomeDexmedetomidinePlaceboP value
Participants taking oral morphine3425P = 0.10
  • Participants taking oral morphine: 25/62 vs 34/60

Pain at rest or on movement

No effect of dexmedetomidine

Other outcomes, incl. durations of sensory and motor block

Similar

Safety

Events

OutcomeDexmedetomidinePlaceboP value
Intra-operative hypotension5027P < 0.001
  • Intra-operative hypotension: 27/62 vs 50/60

Original publication

A randomised controlled trial of intravenous dexmedetomidine added to dexamethasone for arthroscopic rotator cuff repair and duration of interscalene block. Anaesthesia. Published 14 December 2022. doi:10.1111/anae.15942

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.